Title:
USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] FOR TREATMENT OF CANCER
Document Type and Number:
Japanese Patent JP2021167360
Kind Code:
A
Abstract:
To provide use of trans-[tetrachlorobis (1H-indazole) ruthenate (III)] for the treatment of cancer.SOLUTION: IT-139, sodium trans-[tetrachlorobis (1H-indazole) ruthenate (III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.SELECTED DRAWING: None
More Like This:
Inventors:
SUZANNE BAKEWELL
JYOTHI SETHURAMAN
JYOTHI SETHURAMAN
Application Number:
JP2021125151A
Publication Date:
October 21, 2021
Filing Date:
July 30, 2021
Export Citation:
Assignee:
INTEZYNE TECH INC
International Classes:
A61K31/416; A61K31/282; A61K31/337; A61K31/436; A61K31/44; A61K31/704; A61K31/706; A61K31/7068; A61K33/24; A61K38/19; A61K38/20; A61K38/21; A61K39/395; A61K45/00; A61P1/18; A61P25/00; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| JP2013531065A | 2013-08-01 |
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Natsuki Morishita